Anti-Obesity Drug Market, By Mechanism of Action (Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs), By Prescription/Non- prescription (Prescription Drugs and OTC Drugs), and By Geography (North America, Europe, Asia-Pacific,

Anti-Obesity Drug Market, By Mechanism of Action (Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs), By Prescription/Non- prescription (Prescription Drugs and OTC Drugs), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Obesity is commonly defined as having too much body mass. Body mass index (BMI) of 30 or higher is the usual benchmark for obesity in adults. Anti-obesity drugs are commonly used for the treatment of obesity. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) has approved several anti-obesity drugs to treat obesity.

Market Dynamics:

Increasing obese population and related chronic diseases, increase in concern of being overweight or obese, increase in demand for anti-obesity drugs, increase in research and development, and the outbreak of COVID-19 are major factors expected to drive growth of the global anti-obesity drug market during the forecast period. For instance, in June 2021, the U.S. FDA approved Semaglutide 2.4 mg for chronic weight management in adults with obesity and/or overweight with at least one weight-related condition (such as high blood pressure or cholesterol, or T2D) for use in addition to a reduced-calorie diet and increased physical activity

Moreover, in January 2021, Novartis announced the results of its Phase II trial of investigational product drug called Bimagrumab. The drug has shown potential for the indication of obesity. The drug is currently being studied in the Novartis pipeline.

Key features of the study:

• This report provides in-depth analysis of the global anti-obesity drug market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global anti-obesity drug market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include VIVUS Inc., Pfizer Inc., Novo Nordisk, Bayer AG, F Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd., Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global anti-obesity drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-obesity drug market.

• Global Anti-Obesity Drug Market, By Mechanism of Action:
• Peripherally Acting Anti-Obesity Drugs
• Centrally Acting Anti-Obesity Drugs
• Global Anti-Obesity Drug Market, By Prescription/Non- prescription:
• Prescription Drugs
• OTC Drugs
• Global Anti-Obesity Drug Market, By Geography:
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America
• Company Profiles:
• VIVUS Inc.
• Pfizer Inc.
• Novo Nordisk
• Bayer AG
• F Hoffmann-La Roche
• Glaxosmithkline
• Arena Pharmaceuticals
• Eisai Co. Ltd.
• Takeda Pharmaceutical Company
• Nalpropion Pharmaceuticals Inc.